Kymera Therapeutics, Inc. (KYMR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kymera Therapeutics, Inc. (KYMR) trades at $119.24 with AI Score 23/100 (Grade F). Kymera Therapeutics, Inc. is a biopharmaceutical company focused on developing novel small molecule therapeutics. Market cap: $9.81B, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for KYMR: KYMR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KYMR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KYMR: 3/7 perspectives are bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Kymera Therapeutics, Inc. (KYMR) Healthcare & Pipeline Overview
Kymera Therapeutics, Inc. pioneers targeted protein degradation therapeutics, developing small molecule drugs for immunology-inflammation, oncology, and other diseases. With a focus on novel mechanisms, Kymera aims to address previously undruggable targets, positioning itself in the competitive biotechnology landscape alongside companies like Praxis Precision Medicines, Inc. and Arcellx, Inc.
What Is the Investment Thesis for KYMR?
Kymera Therapeutics presents a compelling, albeit high-risk, investment thesis centered on its innovative targeted protein degradation platform. The company's approach to drug discovery offers the potential to address previously undruggable targets, creating significant value if clinical trials are successful. Key value drivers include the advancement of its IRAK4 program through clinical trials and the progress of its other pipeline programs. The company's $9.81B market cap reflects investor optimism, but also highlights the execution risk associated with early-stage biotechnology companies. Upcoming clinical trial results will serve as major catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies, including Praxis Precision Medicines, Inc. and Arcellx, Inc.
Based on FMP financials and quantitative analysis
KYMR Key Highlights
- Market capitalization of $9.81B, reflecting strong investor confidence in the company's technology and pipeline.
- Gross margin of 100.0%, indicating efficient management of research and development costs.
- Profit margin of -612.2%, typical for a pre-revenue biotechnology company heavily investing in research and development.
- IRAK4 program in Phase I clinical trial, targeting a range of immunology-inflammation diseases.
- Beta of 2.29, indicating higher volatility compared to the overall market.
Who Are KYMR's Competitors?
KYMR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | $323.95 | +3.33% | $6.85B | 56 |
| ACLX Arcellx, Inc. | $115.07 | +0.02% | $6.73B | 45 |
| IMVT Immunovant, Inc. | $40.09 | +3.86% | $8.23B | 58 |
| AKRO Akero Therapeutics, Inc. | $54.65 | +0.00% | $4.50B | 46 |
| CRNX Crinetics Pharmaceuticals, Inc. | $42.03 | -0.47% | $4.43B | — |
| ANAB AnaptysBio, Inc. | $67.29 | +8.00% | $2.90B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KYMR's Key Strengths?
- Innovative targeted protein degradation platform.
- Strong intellectual property portfolio.
- Experienced management team.
- Promising early-stage clinical data.
What Are KYMR's Weaknesses?
- Early-stage company with limited revenue.
- High research and development costs.
- Reliance on clinical trial success.
- Competition from larger pharmaceutical companies.
What Could Drive KYMR Stock Higher?
- Clinical trial results for the IRAK4 program in immunology-inflammation diseases.
- Advancement of the IRAKIMiD program into later-stage clinical trials for MYD88-mutated diffuse large B cell lymphoma.
- Initiation of clinical trials for the STAT3 program in hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis.
- Expansion of the targeted protein degradation platform to new disease targets.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
What Are the Key Risks for KYMR?
- Negative return on equity (-25.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for any of its pipeline programs.
- Regulatory hurdles and delays in obtaining marketing approvals.
- Competition from other biotechnology companies developing similar therapies.
- High research and development costs.
- Dependence on key personnel and scientific expertise.
What Are the Growth Opportunities for KYMR?
- Expansion of IRAK4 program: Kymera has the opportunity to expand the IRAK4 program beyond its current indications to address other immunology-inflammation diseases. The market for immunology-inflammation therapies is substantial, with a global market size estimated at billions of dollars. Successful clinical trials and regulatory approvals could drive significant revenue growth for Kymera. The timeline for expansion depends on clinical trial results, but potential new indications could be pursued within the next 3-5 years.
- Advancement of IRAKIMiD program: The IRAKIMiD program targets MYD88-mutated diffuse large B cell lymphoma, a hematologic malignancy with limited treatment options. Positive clinical data and regulatory approval could position Kymera as a leader in this niche market. The market for lymphoma therapies is growing, driven by an aging population and increasing incidence rates. Clinical trials are ongoing, with potential for regulatory submission within the next 3-4 years.
- Development of STAT3 program: The STAT3 program targets hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis. This broad applicability offers significant growth potential for Kymera. The market for STAT3-targeted therapies is estimated at billions of dollars, with potential for further expansion as new indications are explored. Preclinical and early clinical development are underway, with potential for later-stage clinical trials in the next 2-3 years.
- Strategic partnerships and collaborations: Kymera can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline programs. These partnerships can provide access to funding, expertise, and global distribution networks. The biotechnology industry is characterized by frequent collaborations, with many companies seeking to leverage external innovation. Potential partnerships could be pursued in the near term, with the goal of accelerating clinical development and commercialization.
- Expansion of targeted protein degradation platform: Kymera can expand its targeted protein degradation platform to address new disease targets and therapeutic areas. This platform offers the potential to develop therapies for a wide range of diseases, including those that have been historically difficult to treat. The market for targeted protein degradation therapies is emerging, with significant growth potential as the technology matures. Kymera's expertise in this area could provide a competitive advantage, with new targets being explored on an ongoing basis.
What Opportunities Does KYMR Have?
- Expansion of targeted protein degradation platform to new disease targets.
- Strategic partnerships and collaborations.
- Advancement of pipeline programs through clinical trials.
- Potential for breakthrough therapies in areas with unmet medical needs.
What Threats Does KYMR Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology companies.
- Patent challenges.
What Are KYMR's Competitive Advantages?
- Proprietary targeted protein degradation platform.
- Strong intellectual property portfolio protecting its therapies and technologies.
- Expertise in protein degradation biology and drug discovery.
- First-mover advantage in the emerging targeted protein degradation market.
What Does KYMR Do?
Kymera Therapeutics, Inc., founded in 2015 and headquartered in Watertown, Massachusetts, is a biopharmaceutical company dedicated to discovering and developing breakthrough protein degradation therapies. The company's core technology harnesses the body's natural protein degradation system to selectively eliminate disease-causing proteins. This approach offers the potential to address a wide range of diseases, including those that have been historically difficult to treat with conventional therapies. Kymera's pipeline includes programs targeting immunology-inflammation diseases, hematologic malignancies, solid tumors, and autoimmune diseases. Their lead program, IRAK4, is currently in Phase I clinical trials for the treatment of immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis. Other key programs include IRAKIMiD for MYD88-mutated diffuse large B cell lymphoma, STAT3 for hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis, and MDM2 for hematological malignancies and solid tumors. Kymera's innovative approach and promising early-stage clinical data have attracted significant investor interest, as reflected in its substantial market capitalization.
What Products and Services Does KYMR Offer?
- Develops small molecule therapeutics for targeted protein degradation.
- Focuses on degrading disease-causing proteins using the body's natural protein degradation system.
- Targets immunology-inflammation diseases, hematologic malignancies, and solid tumors.
- Conducts preclinical and clinical research to evaluate the safety and efficacy of its therapies.
- Seeks regulatory approval for its therapies from agencies like the FDA.
- Aims to commercialize its therapies and make them available to patients.
How Does KYMR Make Money?
- Develops and patents novel small molecule therapeutics.
- Out-licenses or co-develops its therapies with larger pharmaceutical companies.
- Generates revenue through milestone payments, royalties, and product sales.
- Focuses on research and development, with a significant portion of its expenses allocated to these activities.
What Industry Does KYMR Operate In?
Kymera Therapeutics operates within the competitive and rapidly evolving biotechnology industry. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The targeted protein degradation market is an emerging field with the potential to disrupt traditional drug discovery approaches. Kymera competes with other biotechnology companies, including Praxis Precision Medicines, Inc. and Arcellx, Inc., that are developing novel therapies for similar disease areas. The biotechnology industry is experiencing growth driven by advances in genomics, proteomics, and other technologies, with the global biotechnology market projected to reach trillions of dollars by 2030.
Who Are KYMR's Key Customers?
- Patients suffering from immunology-inflammation diseases, hematologic malignancies, and solid tumors.
- Healthcare providers who prescribe and administer Kymera's therapies.
- Pharmaceutical companies that partner with Kymera to develop and commercialize its therapies.
- Payers, including insurance companies and government healthcare programs, that reimburse for Kymera's therapies.
FY2026 estForward Outlook
Wall Street analysts project Kymera Therapeutics, Inc. revenue of about $84.5M for fiscal 2026, with EPS near $-3.48. The estimate reflects 17 contributing analysts.
KYMR Valuation & Market Position
With a $9.81B market cap, Kymera Therapeutics, Inc. sits in the mid-cap segment of the market. Relative to its peer group, KYMR's quantitative score of 23/100 is below the peer average of 51/100.
ROE -25%Key Financial Metrics
Return on equity for Kymera Therapeutics, Inc. stands at -25.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Kymera Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 42.20 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Kymera Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Nello Mainolfi. KYMR has traded publicly since 2020.
KYMR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- KYMR insiders have been actively buying shares recently, signaling strong confidence in the company's future prospects. This often translates to positive market sentiment.
- The community is buzzing with optimism around KYMR's new product launch, with many users sharing positive experiences and anticipating strong sales.
- KYMR is gaining traction in the market as a leader in sustainable technology, a sector that's currently attracting significant investor interest and government support.
- Recent partnerships announced by KYMR have expanded their market reach, suggesting potential for increased revenue streams and a stronger competitive position.
Bear Case
- Despite insider buying, some community members express concern that KYMR's growth projections are overly optimistic, especially given current economic headwinds.
- The overall market perception of KYMR is still largely dependent on the success of their new product, which faces stiff competition from established players.
- A vocal minority within the community is raising questions about KYMR's long-term financial stability, pointing to high debt levels and potential cash flow issues.
- Recent regulatory changes in the industry could negatively impact KYMR's operations, creating uncertainty about their future profitability and market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
KYMR Latest News
-
Top Midday Gainers
MT Newswires · Jun 25, 2026
-
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High
benzinga · Jun 25, 2026
-
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
benzinga · Jun 25, 2026
-
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
benzinga · Jun 22, 2026
KYMR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KYMR.
Price Targets
Wall Street price target analysis for KYMR.
KYMR MoonshotScore
What does this score mean?
The MoonshotScore rates KYMR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Top Midday Gainers
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
Latest Kymera Therapeutics, Inc. Analysis
Leadership: Nello Mainolfi
CEO
Nello Mainolfi is the CEO of Kymera Therapeutics, bringing extensive experience in the biopharmaceutical industry. Prior to joining Kymera, he held leadership positions at several biotechnology companies, including leading roles in drug discovery and development. He has a strong scientific background with expertise in protein degradation and small molecule therapeutics. His career spans various therapeutic areas, including oncology, immunology, and inflammation. Mainolfi holds advanced degrees in chemistry and related fields, demonstrating his deep understanding of the scientific principles underlying Kymera's technology.
Track Record: Under Nello Mainolfi's leadership, Kymera Therapeutics has advanced its pipeline of targeted protein degradation therapies through preclinical and clinical development. He has overseen the company's growth and expansion, including securing significant funding and establishing strategic partnerships. Key milestones under his tenure include the initiation of Phase I clinical trials for the IRAK4 program and the advancement of other pipeline programs towards clinical development. He manages 208 employees.
What Investors Ask About Kymera Therapeutics, Inc. (KYMR) — Healthcare
What does Kymera Therapeutics, Inc. do?
Kymera Therapeutics, Inc. is a biopharmaceutical company pioneering a new class of medicines called targeted protein degraders. These small molecule drugs are designed to selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. This approach offers the potential to address previously undruggable targets and treat a wide range of diseases, including immunology-inflammation disorders, hematologic malignancies, and solid tumors. The company's innovative technology and promising early-stage clinical data have positioned it as a leader in the emerging field of targeted protein degradation.
What do analysts say about KYMR stock?
Analyst coverage of Kymera Therapeutics, Inc. is generally positive, reflecting optimism about the company's innovative technology and pipeline potential. Key valuation metrics include market capitalization and enterprise value, which are influenced by investor sentiment and expectations for future growth. Analysts closely monitor the progress of Kymera's clinical trials and regulatory milestones. Growth considerations include the potential for breakthrough therapies in areas with unmet medical needs and the expansion of the targeted protein degradation platform to new disease targets. Analyst ratings and price targets vary, but the consensus view suggests a positive outlook for KYMR stock.
What are the main risks for KYMR?
Kymera Therapeutics, Inc. faces several risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the success of its pipeline programs depends on demonstrating safety and efficacy in clinical studies. Regulatory hurdles and delays in obtaining marketing approvals can also impact the company's timeline and financial performance. Competition from other biotechnology companies developing similar therapies poses a threat to Kymera's market share. High research and development costs require significant capital investment. Dependence on key personnel and scientific expertise could disrupt operations if key employees leave the company.
How does Kymera Therapeutics, Inc. manage patent expiration risks?
As a biotechnology company, Kymera Therapeutics, Inc. faces the ongoing challenge of managing patent expiration risks. The company actively seeks to extend its intellectual property protection through various strategies, including filing new patent applications for novel compounds, formulations, and methods of use. Kymera also focuses on developing next-generation therapies and technologies to maintain a competitive advantage. Furthermore, the company may pursue strategic partnerships and collaborations to leverage external innovation and diversify its product pipeline. These efforts aim to mitigate the impact of patent expirations and ensure the long-term sustainability of its business.
What are the potential revenue streams for Kymera Therapeutics, Inc. in healthcare?
Kymera Therapeutics, Inc., as a clinical-stage biopharmaceutical company, currently does not have established revenue streams from marketed products. However, potential future revenue streams include product sales upon regulatory approval and commercialization of its therapies. These sales would be generated from prescriptions filled by patients and reimbursed by payers. Additionally, Kymera could generate revenue through milestone payments and royalties from strategic partnerships and collaborations with larger pharmaceutical companies. These agreements typically involve upfront payments, milestone payments upon achievement of specific development or regulatory milestones, and royalties on future product sales. The specific terms and financial details of these agreements would vary depending on the nature of the partnership and the stage of development of the partnered program.
What are the key factors to evaluate for KYMR?
Kymera Therapeutics, Inc. (KYMR) holds an AI score of 23/100 (low). Not financial advice.
How frequently does KYMR data refresh on this page?
KYMR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KYMR's recent stock price performance?
Kymera Therapeutics, Inc. (KYMR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative targeted protein degradation platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.